Use of ecarin chromogenic assay during bivalirudin anticoagulation in adult extracorporeal membrane oxygenation

Thromb Res. 2023 Aug:228:42-45. doi: 10.1016/j.thromres.2023.05.022. Epub 2023 May 29.

Authors

Abby K Krauter¹, Scott D Nei², Troy G Seelhammer³, J Kyle Bohman³, Patrick M Wieruszewski⁴

Affiliations

¹ Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
² Department of Pharmacy, Mayo Clinic, Rochester, MN, USA; Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
³ Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
⁴ Department of Pharmacy, Mayo Clinic, Rochester, MN, USA; Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA. Electronic address: [email protected].

PMID: 37269715
DOI: 10.1016/j.thromres.2023.05.022

No abstract available

Publication types

Letter

MeSH terms

Adult
Anticoagulants / therapeutic use
Extracorporeal Membrane Oxygenation* / adverse effects
Heparin
Hirudins / pharmacology
Humans
Peptide Fragments / therapeutic use
Recombinant Proteins / therapeutic use
Retrospective Studies

Substances

bivalirudin
ecarin
Hirudins
Peptide Fragments
Anticoagulants
Recombinant Proteins
Heparin